Inactive Instrument

Clovis Oncology, Inc.

CLVS.Q

US1894641000

Biotechnology & Medical Research

Clovis Oncology, Inc. Announces Resignation of Andrew Allen as Executive Vice President of Clinical & Pre-Clinical Development & Chief Medical Officer

August 12, 2015 at 05:05 pm

Dr. Andrew Allen resigned from the position of Executive Vice President of Clinical & Pre-Clinical Development & Chief Medical Officer of Clovis Oncology, Inc. effective July 31, 2015.

Latest news about Clovis Oncology, Inc.

Clovis Oncology, Inc. Went Out of Business	23-07-10	CI
Revised Third Amened Joint Liquidation Plan Approved for Clovis Oncology, Inc.	23-06-16	CI
Third Amended Joint Liquidation Plan Filed by Clovis Oncology, Inc.	23-06-03	CI
Second Amended Joint Liquidation Plan Filed by Clovis Oncology, Inc.	23-05-31	CI
Zr pharma& GmbH completed the acquisition of certain assets and rights associated with Rubraca from Clovis Oncology, Inc. (OTCPK:CLVS.Q).	23-04-30	CI
US FDA panel backs restricted use of AstraZeneca's prostate cancer drug (April 28)	23-04-28	RE
First Motion for Exclusivity Period Extension Approved For Clovis Oncology, Inc.	23-04-28	CI
Combined Hearing for Disclosure Statement and Plan Approved On Interim Basis for Clovis Oncology, Inc.	23-04-21	CI
First Amended Liquidation Plan and Disclosure Statement Filed by Clovis Oncology, Inc.	23-04-19	CI
Motion for Asset Sale Approved for Clovis Oncology, Inc.	23-04-12	CI
First Motion for Exclusivity Period Extension Filed by Clovis Oncology, Inc.	23-04-10	CI
Zr pharma& GmbH entered into an asset purchase agreement to acquire certain assets and rights associated with Rubraca from Clovis Oncology, Inc. (OTCPK:CLVS.Q) for approximately $140 million.	23-04-05	CI
UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula	23-04-05	RE
Auction Result Filed for Clovis Oncology, Inc.	23-03-31	CI
North American Morning Briefing : Investor Mood -3-	23-03-29	DJ
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Joint Liquidation Plan and Disclosure Statement Filed by Clovis Oncology, Inc.	23-03-14	CI
Amended DIP Financing Approved for Clovis Oncology, Inc.	23-03-13	CI
North American Morning Briefing : Stock Futures -3-	23-03-08	DJ
Notice of Reschedule of Auction filed by Clovis Oncology, Inc.	23-03-08	CI
Notice for Auction Cancellation and Selection of Successful Bidder Filed by Clovis Oncology, Inc.	23-03-06	CI
North American Morning Briefing : Chinese -2-	23-03-01	DJ
North American Morning Briefing : Fed Minutes Eyed -2-	23-02-22	DJ
Final DIP Financing Approved for Clovis Oncology, Inc.	23-01-23	CI
Bidding Procedure Approved for Clovis Oncology, Inc.	23-01-23	CI

Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR Î±/Î²) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs